Amyloid-beta Dynamics Correlate with Neurological Status in the Injured Human Brain

Overview

Journal Science

Specialty Science

Date 2008 Aug 30

PMID 18755980

Citations 155

Authors

David L Brody

Sandra Magnoni

Kate E Schwetye

Michael L Spinner

Thomas J Esparza

Nino Stocchetti

Gregory J Zipfel

David M Holtzman

Affiliations

Soon will be listed here.

Abstract

The amyloid-beta peptide (Abeta) plays a central pathophysiological role in Alzheimer's disease, but little is known about the concentration and dynamics of this secreted peptide in the extracellular space of the human brain. We used intracerebral microdialysis to obtain serial brain interstitial fluid (ISF) samples in 18 patients who were undergoing invasive intracranial monitoring after acute brain injury. We found a strong positive correlation between changes in brain ISF Abeta concentrations and neurological status, with Abeta concentrations increasing as neurological status improved and falling when neurological status declined. Brain ISF Abeta concentrations were also lower when other cerebral physiological and metabolic abnormalities reflected depressed neuronal function. Such dynamics fit well with the hypothesis that neuronal activity regulates extracellular Abeta concentration.

Citing Articles

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease.

Hey J, Yu J, Abushakra S, Schaefer J, Power A, Kesslak P Clin Pharmacokinet. 2025; .

PMID: 39907966 DOI: 10.1007/s40262-025-01482-8.

Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementia.

Schrempel S, Kottwitz A, Piechotta A, Gnoth K, Buschgens L, Hartlage-Rubsamen M Acta Neuropathol. 2024; 148(1):78.

PMID: 39625512 PMC: 11615120. DOI: 10.1007/s00401-024-02824-9.

Non-rapid eye movement sleep slow-wave activity features are associated with amyloid accumulation in older adults with obstructive sleep apnoea.

Carvalho D, Kremen V, Mivalt F, St Louis E, McCarter S, Bukartyk J Brain Commun. 2024; 6(5):fcae354.

PMID: 39429245 PMC: 11487750. DOI: 10.1093/braincomms/fcae354.

Pathological and neurochemical correlates of locus coeruleus functional network activity.

Parent J, Cassady K, Jagust W, Berry A Biol Psychol. 2024; 192:108847.

PMID: 39038634 PMC: 11464174. DOI: 10.1016/j.biopsycho.2024.108847.

Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.

Haut F, Argyrousi E, Arancio O Int J Mol Sci. 2024; 25(1).

PMID: 38203429 PMC: 10779219. DOI: 10.3390/ijms25010259.

References

Games D, Buttini M, Kobayashi D, Schenk D, Seubert P . Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis. 2006; 9(3 Suppl):133-49. DOI: 10.3233/jad-2006-9s316. View

Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K . Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997; 94(4):1550-5. PMC: 19829. DOI: 10.1073/pnas.94.4.1550. View

Teasdale G, Jennett B . Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974; 2(7872):81-4. DOI: 10.1016/s0140-6736(74)91639-0. View

Abrahamson E, Ikonomovic M, Ciallella J, Hope C, Paljug W, Isanski B . Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol. 2005; 197(2):437-50. DOI: 10.1016/j.expneurol.2005.10.011. View

Klyubin I, Walsh D, Lemere C, Cullen W, Shankar G, Betts V . Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005; 11(5):556-61. DOI: 10.1038/nm1234. View

Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T . APP processing and synaptic function. Neuron. 2003; 37(6):925-37. DOI: 10.1016/s0896-6273(03)00124-7. View

Corbett R, Laptook A, Weatherall P . Noninvasive measurements of human brain temperature using volume-localized proton magnetic resonance spectroscopy. J Cereb Blood Flow Metab. 1997; 17(4):363-9. DOI: 10.1097/00004647-199704000-00001. View

Hutchinson P, OConnell M, Al-Rawi P, Maskell L, Kett-White R, Gupta A . Clinical cerebral microdialysis: a methodological study. J Neurosurg. 2000; 93(1):37-43. DOI: 10.3171/jns.2000.93.1.0037. View

Hillered L, Vespa P, Hovda D . Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005; 22(1):3-41. DOI: 10.1089/neu.2005.22.3. View

10.

Ronne-Engstrom E, Cesarini K, Enblad P, Hesselager G, Marklund N, Nilsson P . Intracerebral microdialysis in neurointensive care: the use of urea as an endogenous reference compound. J Neurosurg. 2001; 94(3):397-402. DOI: 10.3171/jns.2001.94.3.0397. View

11.

Buckner R, Snyder A, Shannon B, LaRossa G, Sachs R, Fotenos A . Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005; 25(34):7709-17. PMC: 6725245. DOI: 10.1523/JNEUROSCI.2177-05.2005. View

12.

Roberts G, Gentleman S, Lynch A, Murray L, Landon M, Graham D . Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1994; 57(4):419-25. PMC: 1072869. DOI: 10.1136/jnnp.57.4.419. View

13.

Seubert P, Esch F, Lee M, Dovey H, Davis D, Sinha S . Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992; 359(6393):325-7. DOI: 10.1038/359325a0. View

14.

Shankar G, Li S, Mehta T, Garcia-Munoz A, Shepardson N, Smith I . Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14(8):837-42. PMC: 2772133. DOI: 10.1038/nm1782. View

15.

Tesco G, Koh Y, Kang E, Cameron A, Das S, Sena-Esteves M . Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007; 54(5):721-37. PMC: 1973166. DOI: 10.1016/j.neuron.2007.05.012. View

16.

Walsh D, Klyubin I, Fadeeva J, Cullen W, Anwyl R, Wolfe M . Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416(6880):535-9. DOI: 10.1038/416535a. View

17.

Smith D, Nakamura M, McIntosh T, Wang J, Rodriguez A, Chen X . Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am J Pathol. 1998; 153(3):1005-10. PMC: 1853010. DOI: 10.1016/s0002-9440(10)65643-x. View

18.

Bateman R, Wen G, Morris J, Holtzman D . Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007; 68(9):666-9. DOI: 10.1212/01.wnl.0000256043.50901.e3. View

19.

Lesne S, Koh M, Kotilinek L, Kayed R, Glabe C, Yang A . A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006; 440(7082):352-7. DOI: 10.1038/nature04533. View

20.

Selkoe D . Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 2002; 110(10):1375-81. PMC: 151820. DOI: 10.1172/JCI16783. View